 Subjects will be recruited and a baseline of physiological, neurological and hematological profile established for each patient. Forty-four subjects 20 in the active arm, 20 in the placebo arm, and 2 replacements for each arm will receive 4 gday Lovaza tablets or placebo for a period of 6 months. All subjects will receive a physical and neurological exam as well as neurovascular function testing. This includes nerve conduction studies, quantitative sensory testing, quantitative autonomic testing, and skin blood flow testing, which includes, ischemia reperfusion. Lab tests include an insulin resistance profile, hepatic and renal function profiles, lipid profile, C-reactive protein, thyroid stimulating hormone, and fatty acids. Other tests include inflammatory markers such as adiponectin and tumor necrosis factor-α. The study is powered to detect differences in microvascular function after 6 months of Lovaza and differences in ethnic responses. 